riociguat group 10/490 (2.0%) vs 2/214 (0.9%) in placebo group, with one patient in riociguat group having a fatal outcome. In addition, pulmonary haemorrhage (3/642, 0.5%) occurred during the long-term extension period and all of them had a fatal outcome. During the study, the dose of the study drug was decreased in 18 patients (10%) in the riociguat group.
In PH associated with chronic obstructive pulmonary diseases
The impact of a riociguat single dose25 was
assessed on haemodynamics, gas exchange, and lung function in 22 patients with PH associated with chronic obstructive pulmonary disease (COPD) receiving riociguat 1 or 2.5mg during right heart catheterisation. Riociguat caused significant improvements in mPAP (1mg: –11%; 2.5mg: –15%) and PVR (1mg: –15%; 2.5mg: –33%). No relevant changes in lung function or gas exchange were observed. Single doses of riociguat were well-tolerated and showed promising haemodynamic effects without changes of gas exchange or lung function.
In symptomatic PH associated with left ventricular systolic dysfuntion In LEPHT study26
riociguat at doses of 0.5–2.0 mg for 16 weeks did not result in statistically significant improvements in mPAP compared with placebo in patients with symptomatic PH associated with left ventricular systolic dysfunction. However, treatment in the 2.0mg target-dose arm (compared with placebo) resulted in consistent improvements in other haemodynamic parameters measured invasively and by echocardiography (left ventricular ejection fraction).
In PH associated with preserved left heart failure (HFpEF)
The acute haemodynamic effects27 of 26
riociguat were analysed in clinically stable patients with PH and HFpEF (left ventricular ejection fraction > 50%, mPAP ≥ 25mm Hg, and pulmonary arterial wedge pressure (PAWP) >15 mmHg). The patients were randomised to single oral doses of placebo or riociguat (0.5, 1, or 2mg). Riociguat resulted with no significant change in peak decrease in mPAP compared with placebo after six hours. However, riociguat 2mg significantly increased stroke volume (+9 ml; p=0.04) and decreased systolic blood pressure (–12 mmHg; p=0.03) and right
ventricular end-diastolic area (–5.6cm2
p=0.04), without significantly changing heart rate, PAWP, transpulmonary pressure gradient, or PVR. In patients with HFpEF and PH, riociguat showed no significant effect on haemodynamics, but it improved exploratory haemodynamic and echocardiographic parameters.
Riociguat is an efficacious treatment for PAH and CTEPH. The US Food and Drug Administration approved riociguat (Adempas®
, Bayer) on 8 October 2013. It
is indicated for the treatment of adult patients with inoperable or persistent/ recurrent CTEPH after PEA, and adult patients with PAH. European Medicines Agency’ approval was granted in March 2014. Currently it is the only treatment approved in both indications: PAH and adult patients with inoperable or persistent/recurrent CTEPH after PEA. l
References 1. Humbert M et al. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425–36.
2. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214–21.
3. Tuder RM et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925–32.
4. Giaid A et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993;341:1550–4.
5. Lucas KA et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000;52:375–414.
6. Stasch JP et al. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011;123:2263–73.
7. Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim Biophys Acta 1999;1411:334–50.
8. Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signalling and drug development. N Engl J Med 2006;355:2003–11.
9. Lubos E et al. Role of oxidative stress and nitric oxide in atherothrombosis. Front Biosci 2008;13:5323–44.
10. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 2009;122:216–38.
11. Vachiery JL. Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy. Adv Ther 2011;28:251–69.
12. Bayer HealthCare AG. Investigator’s Brochure BAY 63-2521/Riociguat. Version 14.0 Date 22 Apr 2013.
13. Schermuly RT et al. Expression and function of soluble guanylate cyclase in pulmonary arterial
hypertension. Eur Respir J 2008;32:881–91.
14. Lang M et al. The soluble guanylate cyclise stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PloS One 2012;7:e43433.
15. White RJ et al. Oral treprostinil diethanolamine provides sustained therapeutic plasma concentrations over a wide range of doses in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;177:A261. Poster presented at: American Thoracic Society International Conference 2008.
16. Frey R et al. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008;48:926–34.
17. Grimminger F et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009;33:785–92.
18. Skoro-Sajer N et al. Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy. Thorax 2014;69: 116–22.
19. Ghofrani HA et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330–40.
20. Rubin LJ et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).Eur Resp J 2015;45: 130–13.
21. Galie N et al. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Resp J 2015;45:1314–22.
22. Rosenkranz S et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart 2015;doi:10.1136/ heartjnl-2015-307832.
23. Ghofrani HA et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369:319–29.
24. Simonneau G et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Resp J 2015;45:1293–302.
25. Ghofrani HA et al. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease. Pulm Circ 2015;5:296–304.
26. Bonderman D et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013;128:502–11.
27. Bonderman D et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest 2014;146:1274–85.
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48